{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ding XJ"],"funding":["Natural Science Foundation of Tianjin Municipality","National Natural Science Foundation of China","Tianjin Key Medical Discipline (Specialty) Construction Project"],"pagination":["e70028"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11868026"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(5)"],"pubmed_abstract":["Background
Improving the \"cold\" tumor immune microenvironment (TIME) of small-cell lung cancer (SCLC) represents a promising therapeutic approach. The metabolite lactate plays a crucial role in shaping the immune-cold tumor microenvironment (TME) and facilitating tumor progression. Phosphoglycerate kinase 1 (PGK1) is a key enzyme involved in tumor lactate metabolism. This study demonstrates that ACT001 improves the TIME of SCLC through inhibiting lactate production by targeting PGK1.Methods
The cytotoxic effects of ACT001 on SCLC cell lines NCI-H1688 and NCI-H446 were evaluated using MTT assay, clone formation, EdU incorporation, wound healing, and invasion assays. To elucidate the mechanism of action of ACT001, proteomic techniques, pull-down assays, LC-MS/MS, surface plas"],"journal":["Thoracic cancer"],"pubmed_title":["ACT001 Suppresses the Malignant Progression of Small-Cell Lung Cancer by Inhibiting Lactate Production and Promoting Anti-Tumor Immunity."],"pmcid":["PMC11868026"],"funding_grant_id":["82172635","21JCYBJC01000","82273794","TJYXZDXK-010A","82203628","82272686"],"pubmed_authors":["Wang WJ","Lu YX","Ding XJ","Qin TT","Huang DZ","Mei T","Chen Y","Xi XN","Wang JY"],"additional_accession":[]},"is_claimable":false,"name":"ACT001 Suppresses the Malignant Progression of Small-Cell Lung Cancer by Inhibiting Lactate Production and Promoting Anti-Tumor Immunity.","description":"Background
Improving the \"cold\" tumor immune microenvironment (TIME) of small-cell lung cancer (SCLC) represents a promising therapeutic approach. The metabolite lactate plays a crucial role in shaping the immune-cold tumor microenvironment (TME) and facilitating tumor progression. Phosphoglycerate kinase 1 (PGK1) is a key enzyme involved in tumor lactate metabolism. This study demonstrates that ACT001 improves the TIME of SCLC through inhibiting lactate production by targeting PGK1.Methods
The cytotoxic effects of ACT001 on SCLC cell lines NCI-H1688 and NCI-H446 were evaluated using MTT assay, clone formation, EdU incorporation, wound healing, and invasion assays. To elucidate the mechanism of action of ACT001, proteomic techniques, pull-down assays, LC-MS/MS, surface plas","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2025-04-22T20:07:57.092Z","creation":"2025-04-06T03:05:01.695Z"},"accession":"S-EPMC11868026","cross_references":{"pubmed":["40016971"],"doi":["10.1111/1759-7714.70028"]}}